Subhash C.
- Country
- Czechia
- Department
- Oddělení radioterapie a onkologie
Research Overview
- Phase 3 Randomized Study of Telisotuzumab Vedotin vs. Docetaxel in c-Met Overexpressing EGFR Wildtype Non-Squamous NSCLC
- Phase 3 Randomized, Double-blind, Placebo-controlled Study of Apalutamide and GnRH Agonist in High-risk Localized or Locally Advanced Prostate Cancer with Primary Radiation Therapy
- Phase 3 Study of BAY 2927088 vs. Standard of Care in HER2-Mutant Advanced NSCLC
Data & Insights
Has run more than one trial at 80 of 303 partner sites.
Specializations
Lung Cancer Specialization
This investigator focuses on advanced treatments for non-small cell lung cancer (NSCLC), particularly concentrating on cases involving specific genetic mutations and molecular markers.
- HER2 Mutated NSCLC
- Non-squamous NSCLC
- EGFR Wildtype Cases
The investigator's work encompasses innovative therapeutic approaches for patients with c-Met overexpressing and HER2 (ERBB2) mutations.
Targeted Therapy Research
Specializing in the evaluation of targeted therapeutic agents for treating advanced lung cancers, with particular attention to molecular-based treatments.
- Novel Therapeutic Compounds
- Comparative Treatment Studies
- Progression-Free Survival Assessment
The investigator evaluates treatment efficacy through progression-free survival and overall survival metrics in specific patient populations.
Precision Medicine
Focuses on developing personalized treatment approaches based on specific genetic and molecular characteristics of lung cancer.
- Biomarker-Driven Therapy
- Molecular Profiling
- Treatment Response Analysis
The investigator's research emphasizes molecular targeted therapies and their comparison with standard treatment options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.